QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
News Nov 13, 2014
QIAGEN N.V. has announced that it has entered into a master collaboration agreement with the Swiss pharmaceutical company Novartis AG to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline.
The non-exclusive agreement with Novartis creates a framework for collaborations that would include developing QIAGEN companion diagnostics to guide treatment decisions for Novartis pharmaceutical products. The scope of the collaboration can cover all QIAGEN platforms, indications or biomarkers. Financial terms of the agreement were not disclosed.
The collaboration with Novartis is the ninth master framework agreement reached by QIAGEN for the development of companion diagnostics, underscoring its position as the preferred partner to pharma companies.
“We are very pleased to be working with Novartis in the development and commercialization of companion diagnostics to support their innovative pharmaceutical products. Healthcare providers are increasingly benefitting from personalized treatment strategies based on genomic insights, to select the right drug for the right patient at the right time and in the right dose," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “This broad agreement gives Novartis and QIAGEN the flexibility to pursue co-development projects. We are committed working with our partners like Novartis to make improvements in life possible.”
QIAGEN is pursuing more than 20 collaborative projects with Pharma and biotech companies to develop, validate and market companion diagnostics designed to guide the treatment of cancers and other diseases. Around the world, QIAGEN already markets companion diagnostics based on molecular biomarkers, and the company has a growing portfolio of novel targets in development.
The companion diagnostic programs span a range of platforms for molecular testing. A number of the diagnostics are real-time PCR assays for analysis on QIAGEN’s Rotor-Gene Q, a component of the QIAsymphony family of automated instruments. For example, QIAGEN received FDA approvals in 2012 and 2014 for its therascreen® KRAS RGQ PCR Kit in colorectal cancer and in 2013 for the therascreen® EGFR test in NSCLC - both running on Rotor-Gene Q.
In addition, QIAGEN is a leader in developing universal solutions for NGS platforms which include a broad number of gene panels that cover an extensive range of cancer-related genes and gene regions. A recent addition to the portfolio of QIAGEN platforms for companion diagnostics is the multi-modal, multi-analyte Modaplex system, which enables laboratories to analyze multiple sample types simultaneously for dozens of DNA and RNA biomarkers.
QIAGEN also is pioneering companion diagnostics based on blood or other fluid samples for medical situations that make surgical biopsies difficult. QIAGEN has collaborations to develop first-in-class, non-invasive tests for genetic biomarkers using liquid biopsies, which use blood or other fluid samples rather than tissue samples.
QIAGEN’s liquid biopsy technologies include industry-leading kits for processing free-circulating DNA and RNA, genomic material from single cells, or exosomes circulating in the body.
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019